PACTR2009010001152787已完成未知
An open randomized phase I/II study evaluating safety and immunogenicity of a candidate HIV-1 vaccine, MVA.HIVA, administered to healthy infants born
Medical Research Council UK0 个研究点目标入组 72 人开始时间: 2008年12月10日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Mother Inclusion Criteria
- •a.Second or third trimester of pregnancy, as determined by a clinical exam and reported menstrual history
- •b.Written informed consent
- •c.> 18 years of age
- •d.Confirmation of HIV-1 infection documented by ELISA
- •e.CD4 count > 350 cells/ ¿l in the screening blood specimen and at 6 weeks after delivery
- •f.Stated willingness to receive HAART during pregnancy and breastfeeding (if applicable)
- •g.Stated intent to deliver at Kenyatta National Hospital
- •h.Stated intent to remain in the Nairobi area for at least a year after delivery
- •Infant Inclusion Criteria
- •a.Healthy infants
- •b.< 3 days of age (day of birth = Day 0) at enrolment
- •c.Birth weight > 2500 grams
- •d.Born to an eligible woman
- •e.Written informed consent by parent
排除标准
- •Mother Exclusion Criteria
- •a.WHO stage 3 or 4 disease progression as determined by clinical evaulation
- •b.Prior participation in any HIV-1 vaccine or drug trial
- •c.Receipt of any investigational agent during this pregnancy
- •d.Receipt of blood products, immunoglobulin, or immunotherapy during this pregnancy
- •e.Evidence of clinically significant disease that would compromise the ability of the participant to complete the study or the study requirements as determined by the study clinician
- •f.Known multiple gestation in the current pregnancy
- •Infant Exclusion Criteria
- •a.HIV infection, as determined by a filter paper and/or RNA test prior to vaccination.
- •b.Participation in any other HIV-1 vaccine or drug trial.
- •c.Failure to receive all standard KEPI immunizations according to national immunization programme (Table 5).
- •d.Weight for age z-scores outside of 2 standard deviations of normal at the time of vaccination.
- •e.Acute disease at the time of vaccination (acute disease is defined as the presence of a moderate or severe illness with or without fever). All vaccines can be administered to persons with a minor illness such as diarrhoea, mild upper respiratory tract infection with or without low-grade febrile illness, i.e., temperature of <37.5 °C).
- •f.Axillary temperature of ¿ 37.5 °C at the time of vaccination.
- •g.Any clinically significant abnormal finding on screening from biochemistry or haematology by the time of vaccination.
- •h.History of allergic disease or reactions likely to be exacerbated by any component of the vaccine, e.g., egg products.
- •i.Presence of any underlying disease that compromises the diagnosis and evaluation of response to the vaccine.
- •j.Any other on-going chronic illness requiring hospital specialist supervision.
- •k.Administration of immunoglobulins and/or any blood products within one month preceding the planned administration of the vaccine candidate.
- •l.Any history of anaphylaxis in reaction to vaccination.
- •m.Research Physician's assessment of lack of willingness by parents to participate and comply with all requirements of the protocol, or identification of any factor felt to significantly increase the infant's risk of suffering an adverse outcome.
- •n.Likelihood of travel away from the study area.
研究者
相似试验
进行中（未招募）
1 期
A randomized phase II pilot study to evaluate safety and efficacy of the addition of vismodegib to standard neoadjuvant chemotherapy in triple negative breast cancer patients.MedDRA version: 17.1Level: PTClassification code 10057654Term: Breast cancer femaleSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: PTClassification code 10006200Term: Breast cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: PTClassification code 10006202Term: Breast cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: PTClassification code 10006201Term: Breast cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: PTClassification code 10006199Term: Breast cancer stage ISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Breast cancerEUCTR2014-001287-35-ESClínica Universidad de Navarra/Universidad de Navarra40
尚未招募
不适用
Safety and Efficacy of SCM-AGH in Subjects With Moderate to Severe Atopic DermatitisKCT0004806SCM Lifescience92
未知
1 期
A Phase 1, 2, Open-label Study to Evaluate the Safety and Tolerability of Vandetanib 300 mg/Day in Japanese Patients With Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinomanresectable Locally Advanced or Metastatic, Medullary Thyroid CarcinomaJPRN-jRCT2080221951AstraZeneca
已完成
1 期
A Study of Lazertinib as Monotherapy or in Combination with Amivantamab in Participants with Advanced Non-small Cell Lung CancerJPRN-jRCT2080224850Janssen Pharmaceutical K.K.520
已完成
不适用
A Phase Ib/II, open label study evaluating the safery and pharmacokinetics of GDC-0199 (ABT-199) in combination with Rituximab (R) or Obinutuzumab (G) plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in patients with B Cell non-hodgkin's lymphoma (NHL) and DLBCNon-Hodgkin's Lymphoma10025320NL-OMON45171Hoffmann-La Roche21